CLINICAL RESEARCH: CLINICAL TRIAL
Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery DiseaseThe PEACE Trial
Torbjørn Omland, MD, PhD, MPH*, ,2,*,
Marc S. Sabatine, MD, MPH , ,3,
Kathleen A. Jablonski, PhD||,1,4,
Madeline Murguia Rice, PhD||,1,4,
Judith Hsia, MD||,5,
Ragnhild Wergeland, MT#,
Sverre Landaas, MD, PhD**,
Jean L. Rouleau, MD, FACC,,
Michael J. Domanski, MD, FACC,
Christian Hall, MD, PhD*,,6,
Marc A. Pfeffer, MD, PhD, FACC,,
Eugene Braunwald, MD, FACC, for the PEACE Investigators
* Department of Medicine, Akershus University Hospital, Lorenskog, Norway
Faculty of Medicine, University of Oslo, Oslo, Norway
Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
Department of Medicine, Harvard Medical School, Boston, Massachusetts
|| George Washington University, Rockville, Maryland, and Washington, DC
# Department of Medical Biochemistry, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
** Department of Clinical Chemistry, Ullevaal University Hospital, Oslo, Norway
Montreal Heart Institute, Montreal, Quebec, Canada
Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada
National Heart, Lung, and Blood Institute, Bethesda, Maryland.
Manuscript received December 6, 2006;
revised manuscript received March 2, 2007,
accepted March 6, 2007.
* Reprint requests and correspondence: Prof. Torbjørn Omland, Department of Medicine, Akershus University Hospital, NO-1478, Lørenskog, Norway. (Email: torbjorn.omland{at}medisin.uio.no).
Objectives: The purpose of this study was to assess the association between B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and the incidence of specific cardiovascular events in low-risk patients with stable coronary disease, the incremental prognostic information obtained from these two biomarkers compared with traditional risk factors, and their ability to identify patients who may benefit from angiotensin-converting enzyme (ACE) inhibition.
Background: The prognostic value of BNPs in low-risk patients with stable coronary artery disease remains unclear.
Methods: Baseline plasma BNP and NT-proBNP concentrations were measured in 3,761 patients with stable coronary artery disease and preserved left ventricular function participating in the PEACE (Prevention of Events With Angiotensin-Converting Enzyme Inhibition) study, a placebo-controlled trial of trandolapril. Multivariable Cox regression was used to assess the association between natriuretic peptide concentrations and the incidence of cardiovascular mortality, fatal or nonfatal myocardial infarction, heart failure, and stroke.
Results: The BNP and NT-proBNP levels were strongly related to the incidence of cardiovascular mortality, heart failure, and stroke but not to myocardial infarction. In multivariable models, BNP remained associated with increased risk of heart failure, whereas NT-proBNP remained associated with increased risk of cardiovascular mortality, heart failure, and stroke. By C-statistic calculations, BNP and NT-proBNP significantly improved the predictive accuracy of the best available model for incident heart failure, and NT-proBNP also improved the model for cardiovascular death. The magnitude of effect of ACE inhibition on the likelihood of experiencing cardiovascular end points was similar, regardless of either BNP or NT-proBNP baseline concentrations.
Conclusions: In low-risk patients with stable coronary artery disease and preserved ventricular function, BNPs provide strong and incremental prognostic information to traditional risk factors.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | BNP = B-type natriuretic peptide | | EDTA = ethylenediaminetetraacetic acid | | NT-proBNP = N-terminal pro-B-type natriuretic peptide |
|
Related Article
-
The Use of B-Type Natriuretic Peptides in Coronary Artery Disease: Utile or Futile?
- Christian Mueller
J. Am. Coll. Cardiol. 2007 50: 215-216.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. S. Sabatine, D. A. Morrow, J. A. de Lemos, T. Omland, S. Sloan, P. Jarolim, S. D. Solomon, M. A. Pfeffer, and E. Braunwald
Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease
Circulation,
January 17, 2012;
125(2):
233 - 240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Guidez, S. Marechaux, C. Pincon, H. Lamour, S. Barrailler, V. Decourcelle, S. Braun, N. Bouabdallaoui, J.-J. Bauchart, J. L. Auffray, et al.
Addition of B-type natriuretic peptide to the GRACE score to predict outcome in acute coronary syndrome: a retrospective (development) and prospective (validation) cohort-based study
Emerg. Med. J.,
April 26, 2011;
(2011)
emj.2010.104422v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Paraskevaidis, E. Tsougos, C. Varounis, N. Dagres, D. Karatzas, J. Parissis, and D. T. Kremastinos
Exercise-induced changes of B-type natriuretic peptide uncover the unknown coronary artery disease in patients with chest pain and normal left ventricular systolic function
European Journal of Cardiovascular Prevention & Rehabilitation,
February 1, 2011;
18(1):
72 - 78.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shah, P. R. Taub, and A. Maisel
Chapter 35 Biomarkers in acute heart failure
The ESC Textbook of Acute and Intensive Cardiac Care,
December 1, 2010;
1(1):
med-9780199584314-chapter - med-9780199584314-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Squire, P. Quinn, H. Narayan, S. Khan, O. Dhillon, K. Ng, D. Kelly, J. Davies, and L. Ng
Identification of potential outcome benefit from ACE inhibition after acute coronary syndrome: a biomarker approach using N-terminal proBNP
Heart,
June 1, 2010;
96(11):
831 - 837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Noman, J. George, and A. Struthers
A new use for B-type natriuretic peptide: to detect myocardial ischaemia in non-heart failure patients
The British Journal of Diabetes & Vascular Disease,
March 1, 2010;
10(2):
78 - 82.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Paniagua, M.-d.-J. Ventura, M. Avila-Diaz, H. Hinojosa-Heredia, A. Mendez-Duran, A. Cueto-Manzano, A. Cisneros, A. Ramos, C. Madonia-Juseino, F. Belio-Caro, et al.
NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients
Nephrol. Dial. Transplant.,
February 1, 2010;
25(2):
551 - 557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Di Angelantonio, R. Chowdhury, N. Sarwar, K. K. Ray, R. Gobin, D. Saleheen, A. Thompson, V. Gudnason, N. Sattar, and J. Danesh
B-Type Natriuretic Peptides and Cardiovascular Risk: Systematic Review and Meta-Analysis of 40 Prospective Studies
Circulation,
December 1, 2009;
120(22):
2177 - 2187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, D. Poldermans, J. J. Bax, E. Boersma, S. De Hert, E. Eeckhout, G. Fowkes, B. Gorenek, M. G. Hennerici, B. Iung, et al.
Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA)
Eur. Heart J.,
November 2, 2009;
30(22):
2769 - 2812.
[Full Text]
[PDF]
|
|
|
|
|
|
|
American College of Cardiology Foundation, American Heart Association, American College of Physicians Task Force on Compe, American Academy of Neurology, American Association of Cardiovascular and Pulmona, American College of Preventive Medicine, American Diabetes Association, American Society of Hypertension, Association of Black Cardiologists, National Lipid Association, et al.
ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease
J. Am. Coll. Cardiol.,
September 29, 2009;
54(14):
1336 - 1363.
[Full Text]
[PDF]
|
|
|
|
|
|
|
WRITING COMMITTEE MEMBERS, C. N. Bairey Merz, M. J. Alberts, G. J. Balady, C. M. Ballantyne, K. Berra, H. R. Black, R. S. Blumenthal, M. H. Davidson, S. B. Fazio, et al.
ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease: A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): Developed in Collaboration With the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association
Circulation,
September 29, 2009;
120(13):
e100 - e126.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C. Palmer, T. G. Yandle, M. G. Nicholls, C. M. Frampton, and A. M. Richards
Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma
Eur J Heart Fail,
September 1, 2009;
11(9):
832 - 839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Nozaki, S. Sugiyama, H. Koga, K. Sugamura, K. Ohba, Y. Matsuzawa, H. Sumida, K. Matsui, H. Jinnouchi, and H. Ogawa
Significance of a Multiple Biomarkers Strategy Including Endothelial Dysfunction to Improve Risk Stratification for Cardiovascular Events in Patients at High Risk for Coronary Heart Disease
J. Am. Coll. Cardiol.,
August 11, 2009;
54(7):
601 - 608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kempf, J.-M. Sinning, A. Quint, C. Bickel, C. Sinning, P. S. Wild, R. Schnabel, E. Lubos, H. J. Rupprecht, T. Munzel, et al.
Growth-Differentiation Factor-15 for Risk Stratification in Patients With Stable and Unstable Coronary Heart Disease: Results From the AtheroGene Study
Circ Cardiovasc Genet,
June 1, 2009;
2(3):
286 - 292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. F. Lewis, S. D. Solomon, K. A. Jablonski, M. M. Rice, F. Clemenza, J. Hsia, A. P. Maggioni, M. Zabalgoitia, T. Huynh, T. E. Cuddy, et al.
Predictors of Heart Failure in Patients With Stable Coronary Artery Disease: A PEACE Study
Circ Heart Fail,
May 1, 2009;
2(3):
209 - 216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Bolliger, M. D. Seeberger, G. A. L. Lurati Buse, P. Christen, B. Rupinski, L. Gurke, and M. Filipovic
A Preliminary Report on the Prognostic Significance of Preoperative Brain Natriuretic Peptide and Postoperative Cardiac Troponin in Patients Undergoing Major Vascular Surgery
Anesth. Analg.,
April 1, 2009;
108(4):
1069 - 1075.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Wedel, J. J.V. McMurray, M. Lindberg, J. Wikstrand, J. G.F. Cleland, J. H. Cornel, P. Dunselman, A. Hjalmarson, J. Kjekshus, M. Komajda, et al.
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide
Eur J Heart Fail,
March 1, 2009;
11(3):
281 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Hamm, H. Mollmann, J.-P. Bassand, and F. van de Werf
CHAPTER 16 Acute Coronary Syndromes
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Winkler, C. Wanner, C. Drechsler, J. Lilienthal, W. Marz, V. Krane, and for the German Diabetes and Dialysis Study Investi
Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients
Eur. Heart J.,
September 1, 2008;
29(17):
2092 - 2099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Daniels, G. A. Laughlin, P. Clopton, A. S. Maisel, and E. Barrett-Connor
Minimally Elevated Cardiac Troponin T and Elevated N-Terminal Pro-B-Type Natriuretic Peptide Predict Mortality in Older Adults: Results From the Rancho Bernardo Study
J. Am. Coll. Cardiol.,
August 5, 2008;
52(6):
450 - 459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Januzzi Jr
Use of Biomarkers to Predict Cardiac Risk from Medications: Getting to the Heart of the Matter
Clin. Chem.,
July 1, 2008;
54(7):
1107 - 1109.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Mueller
The Use of B-Type Natriuretic Peptides in Coronary Artery Disease: Utile or Futile?
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
215 - 216.
[Full Text]
[PDF]
|
|
|
|
